Astellas sued over Adenoscan method patent; GSK's Votrient fought thyroid tumors in study;

 @FiercePharma: J&J exec retires as new recall questions surface. Article | Follow @FiercePharma

> A Florida hospital has sued Astellas Pharma over Adenoscan, a drug given to people unable to run on a treadmill during cardiac stress tests, because the drugmaker argues hospitals would violate a method-of-use patent if they opt for lower-cost generics rather than its brand-name drug. Report

> In a small study, GlaxoSmithKline's cancer drug Votrient helped shrink tumors in nearly half of patients with an advanced form of thyroid cancer, researchers said. Report

> Sanofi-Aventis announced new data showing that adding its injectable diabetes drug Lantus to their drug regimen helped control the disease in patients who didn't fully respond to oral diabetes meds. Sanofi release | Report

> Watson Pharmaceuticals agreed on a licensing deal with the French drugmaker HRA Pharma to market its emergency contraceptive in Canada. Watson release | Report

> Indian marketing approvals for generic drugs may soon get delinked from their patent status, a long-standing demand of India's drugs industry, which depends heavily on the sale of generics. Report

> After a high-pitch awareness campaign by India, leading African nations Uganda, Tanzania and Nigeria are reconsidering their proposals for stringent anti-counterfeiting legislation that would have hampered Indian exports to these countries. Report

Biotech News

@FierceBiotech: Crucell eagerly accepts $2.3B buyout offer from J&J. Article | Follow @FierceBiotech

 @JohnCFierce: Transition's Tony Cruz gambles and fails on diabetes program, collaborating with Lilly. TT-223 bites the dust. Article | Follow @JohnCFierce

> Boehringer faces high-stakes showdown over likely blockbuster. Article

> PLX4032 inspires fierce debate over cancer trial designs. Report

> AZ, BMS tout new batch of PhIII diabetes data for dapagliflozin. Story

> Chelsea shares rocket up after lead drug clears PhIII. News 

Biotech IT News

> Akaza measures rise in OpenClinica users, submissions. News

> Professional guinea pigs show data disregard. Report

> Report: Software makers can aid Tox21 work. Story

> Pending EU regulation drives Virtify PIM solution. Article

And Finally... In a victory against criminal networks distributing counterfeit and adulterated drugs over the internet, the world's second-biggest seller of website addresses will begin screening customers for unapproved drug sales. Report

Suggested Articles

BMS' Opdivo and Yervoy only just won their first approval in previously untreated metastatic NSCLC, but the pair is already making it two.

Wrapping up the legal battle at $10 billion would be a win for Bayer, as it has lost $30 billion in market value since the Monsanto buyout.

Takeda’s Alunbrig has arrived in previously untreated, ALK-positive NSCLC. But there’s plenty of competition waiting to greet it at the door.